Gold prices just lower; monthly gains on track
IRVINE, Calif. - Biomerica, Inc. (NASDAQ: BMRA), a global medical product provider with a current market capitalization of $10.45 million, has declared a 1-for-8 reverse stock split, set to take effect at the start of the trading day on Monday, April 21, 2025. This strategic move aims to elevate the company’s common stock bid price, ensuring compliance with Nasdaq’s minimum bid price requirement for continued listing. The stock has shown significant momentum in 2025, with a year-to-date return of nearly 90%, according to InvestingPro data.
The reverse stock split was authorized by shareholders at the Annual Meeting on December 13, 2024, with the final ratio later determined by the Board of Directors. Consequently, every eight shares of Biomerica’s pre-split stock will consolidate into one post-split share, reducing the total outstanding shares from roughly 20.4 million to 2.5 million. However, the number of authorized shares will remain unchanged. InvestingPro analysis indicates the company maintains a strong liquidity position with a current ratio of 3.76, though it faces challenges with rapid cash consumption.
In addition to the stock consolidation, adjustments will be made to equity awards, option exercise prices, and shares available under stock incentive plans. The par value of the common stock will not be affected by this reverse split.
Biomerica’s common stock will continue trading on The Nasdaq Capital Market under the ticker BMRA, with a new CUSIP number of 09061H406. Shareholders holding fractional shares as a result of the split will see their holdings rounded up to the nearest whole share.
Issuer Direct Corporation, acting as the exchange agent for the reverse stock split, will notify book-entry shareholders of their new share counts post-split. Those holding shares through brokers or banks are not required to take any action, as adjustments will be made automatically.
The reverse stock split is part of Biomerica’s broader strategy to maintain its listing status and improve its financial structure. Further details regarding the split can be found in the company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on September 30, 2024, and on Biomerica’s website.
Biomerica specializes in point-of-care and hospital laboratory diagnostics and therapies, focusing on gastrointestinal and inflammatory diseases. Its patented inFoods® Technology Platform offers a novel approach to managing irritable bowel syndrome (IBS) through diet modification based on individual immunoreactivity to certain foods. The company has achieved modest revenue growth of 5% over the last twelve months, though InvestingPro analysis suggests the stock is currently trading below its Fair Value. Subscribers can access additional insights, including 6 key ProTips and comprehensive financial metrics, to better evaluate this emerging healthcare company.
This announcement is based on a press release statement from Biomerica, Inc.
In other recent news, Biomerica, Inc. has made notable strides with its medical diagnostic solutions. The company achieved a significant regulatory milestone by obtaining the CE marking for its food intolerance products for Crohn’s Disease and Ulcerative Colitis under the European Union’s In Vitro Diagnostic Medical Devices Regulation. This certification allows Biomerica to market these products within the EU, enhancing its global presence. In addition, Biomerica announced promising results from a clinical trial published in the journal Gastroenterology, where its inFoods® IBS blood test significantly reduced abdominal pain and bloating for Irritable Bowel Syndrome patients. The study showed that 59.6% of participants who followed a personalized diet based on the test results met the FDA-standard target for pain reduction.
Furthermore, Biomerica’s Fortel® Prostate Specific Antigen Screening Test received approval from the United Arab Emirates Ministry of Health and Prevention. This test provides rapid results and is part of Biomerica’s strategic expansion in the Middle East, a region facing a growing public health issue with prostate cancer. The Fortel® PSA test has demonstrated high effectiveness, with a sensitivity of 97.2% and an accuracy of 96.7%, according to studies conducted at Ain Shams University in Egypt. These developments reflect Biomerica’s ongoing commitment to providing innovative diagnostic solutions and expanding its market reach internationally.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.